SCHEMBL6469219

SCHEMBL6469219

NC(=O)c1cnc(NCc2ccccc2)cn1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.64
NCOR1 O75376 2/20 0.64
HDAC1 Q13547 1/20 0.64
HDAC2 Q92769 1/20 0.64
HDAC8 Q9BY41 1/20 0.64
HDAC6 Q9UBN7 1/20 0.64
JAK3 P52333 2/20 0.53
IRAK4 Q9NWZ3 2/20 0.53
JAK2 O60674 1/20 0.53
JAK1 P23458 1/20 0.53
TYK2 P29597 1/20 0.53
KDM4E B2RXH2 1/20 0.52
ASPH Q12797 1/20 0.52
RIOX2 Q8IUF8 1/20 0.52
KDM8 Q8N371 1/20 0.52
VNN1 O95497 3/20 0.50
POLB P06746 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PLAU P00749 1/20 0.50
MEN1 O00255 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5040442 0.85 KDM4E (0.54) HDAC3NCOR1HDAC1HDAC2HDAC8
SCHEMBL23746023 0.79 HDAC1 (1.00) HDAC3NCOR1HDAC1HDAC2HDAC8
SCHEMBL5134062 0.79 OPRM1 (0.52) HDAC3NCOR1HDAC1HDAC2HDAC8
SCHEMBL23746025 0.77 HDAC1 (0.76) HDAC3NCOR1HDAC1HDAC2HDAC8
SCHEMBL23746022 0.76 HDAC3 (0.74) HDAC3NCOR1HDAC1HDAC2HDAC8
SCHEMBL6469221 0.76 MEN1 (0.57) HDAC3NCOR1HDAC1HDAC2HDAC8
SCHEMBL11563448 0.75 HCAR3 (0.64) HDAC3HDAC1HDAC2HDAC6VNN1
SCHEMBL2217065 0.74 PLA2G10 (0.49) KDM4EASPHRIOX2KDM8VNN1
SCHEMBL5037303 0.74 SIRT6 (0.46) HDAC3NCOR1HDAC1HDAC2HDAC8
SCHEMBL31390508 0.72 P4HTM (0.47) HDAC3NCOR1HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US claimed
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders APP, BACE1, SNCA HDAC3 1471/4885NCOR1 1991/4885HDAC1 1240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.